Clinical trials: Eczema/Atopic Dermatitis
Eczema, Dermatitis
Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)
This is an efficacy and safety study of up to 12 weeks of desloratadine in Japanese participants with eczema/dermatitis and dermal pruritus.
- Conditions
- Eczema, Dermatitis, Dermal Pruritus
- Trial name
- NCT01916980
- Testing
- Desloratadine 5 mg
- Volunteers
- 94 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis
This is a multi-center, randomized, vehicle controlled, double-blind Phase 2 study in pediatric patients age 2-17 years old with mild to moderate atopic dermatitis.
- Trial name
- NCT03394677
- Testing
- RVT-501 0.5% ointment, Vehicle ointment
- Where
- 7 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Dermavant Sciences GmbH
Dermatitis, Atopic
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who…
- Trial name
- AtDventure (NCT05999799)
- Testing
- GSK1070806
- Where
- 89 sites in United States, Argentina and 15 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
The purpose of this randomized, double blind, placebo controlled, parallel group study is to compare the safety and efficacy of topically applied DS107 cream (1% and 5%) versus vehicle cream, in the treatment of adult patients…
- Trial name
- NCT02925793
- Testing
- DS107, Vehicle cream
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 327 people
- Sponsor
- DS Biopharma
Atopic Dermatitis
A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
The purpose of this study is to assess efficacy, safety, and pharmacokinetics (PK) of QLM3003 Ointment in participants with mild or moderate atopic dermatitis.
- Trial name
- NCT06058000
- Testing
- 1.5% QLM3003, 2% QLM3003
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%; crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice daily (BID) in subjects who are at least 2 years of…
- Trial name
- NCT03539601
- Testing
- Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%
- Where
- 32 sites in United States, Germany and 5 more
- Volunteers
- 237 people
- Sponsor
- Pfizer
Atopic Dermatitis
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
- Trial name
- MORPHEUS (NCT05696392)
- Testing
- ruxolitinib cream
- Where
- 30 sites in United States
- Volunteers
- 47 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
The objective of this study is to compare the efficacy and safety of orally administered DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT03817190
- Testing
- DS107
- Where
- 50 sites in United States, Austria and 3 more
- Volunteers
- 219 people
- Sponsor
- DS Biopharma
Eczema, Atopic Dermatitis
A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin
This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with…
- Conditions
- Eczema, Atopic Dermatitis, Eczema-Prone Skin
- Trial name
- NCT07700745
- Testing
- Rejuvaskin Eczema Body Wash
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Rejuvaskin
Atopic Dermatitis
A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28…
- Trial name
- NCT03000595
- Testing
- SAN007 Cream
- Sponsor
- Santalis Pharmaceuticals, Inc.
Atopic Dermatitis
Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis
Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of Pimecrolimus cream will be evaluated in Japanese pediatric patients with atopic…
- Trial name
- NCT00231998
- Testing
- Pimecrolimus
- Where
- Japan
- Volunteers
- 240 people
- Sponsor
- Novartis
Atopic Dermatitis
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
To evaluate the efficacy and safety of oral administration of dose-dependent EC-18 for 16 weeks in patients with moderate to severe atopic dermatitis
- Trial name
- NCT06487000
- Testing
- EC-18
- Volunteers
- 150 people
- Sponsor
- Enzychem Lifesciences Corporation
Atopic Dermatitis
Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
A Phase I/IIa Clinical Trial to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis
- Trial name
- NCT04725136
- Testing
- FURESTEM-AD inj
- Where
- 2 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT06585202
- Testing
- ATI-2138
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- ADvocate2 (NCT04178967)
- Testing
- Lebrikizumab
- Where
- 89 sites in United States, Bulgaria and 6 more
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Dermatitis, Atopic
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
This study is being conducted to characterize the mechanism of action of crisaborole ointment 2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD) lesions treated with crisaborole ointment 2%…
- Trial name
- NCT03233529
- Testing
- Crisaborole ointment 2% BID
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan
Primary objective: To characterize the use patterns of phototherapy and immunosuppressants prior to dupilumab treatment for adult AD patients, who are eligible for dupilumab reimbursement in Taiwan (e.g., used regimens, reason…
- Trial name
- NCT05442645
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
This is a Phase II, randomized, double-blind, placebo-controlled multicenter study of repeated doses of MOR106 administered as IV infusion.
- Trial name
- IGUANA (NCT03568071)
- Testing
- MOR 106
- Where
- 53 sites in Germany, Hungary and 3 more
- Volunteers
- 207 people
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately.
- Trial name
- ZESTExt (NCT03948334)
- Testing
- ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
- Where
- 48 sites in United States, Belgium and 11 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.